Table 1.
Patient and disease characteristics at baseline.
| Patients (n) | Enrolled Patients; n = 512 | |
|---|---|---|
| Age at study entry (years); n = 505 | Median | 57.0 |
| Range (min–max) | 20.0–87.0 | |
| Age group | ≤60 | 288 (56.2%) |
| >60 | 217 (42.4%) | |
| Missing | 7 (1.4%) | |
| Gender | Male | 218 (42.6%) |
| Female | 294 (57.4%) | |
| Histology | Leiomyosarcoma (LEYO) | 193 (37.7%) |
| LEYO non-uterine | 117 (22.9%) | |
| LEYO uterine | 76 (14.8%) | |
| Liposarcoma (LPS) | 155 (30.3%) | |
| LPS myxoid-round cells | 53 (10.4%) | |
| Dedifferentiated LPS | 50 (9.8%) | |
| Pleomorphic LPS | 15 (2.9%) | |
| Undifferentiated pleomorphic sarcoma | 45 (8.8%) | |
| Synovial sarcoma | 40 (7.8%) | |
| Myxofibrosarcoma | 13 (2.5%) | |
| Solitary fibrous tumor | 11 (2.2%) | |
| Spindle cells non otherwise specified | 11 (2.1%) | |
| Other * | 44 (8.6%) | |
| Site of primary tumor at first diagnosis | Retroperitoneal | 265 (51.8%) |
| Extremity | 157 (30.7%) | |
| Trunk | 38 (7.4%) | |
| Other ** | 30 (5.8%) | |
| Missing | 22 (4.3%) | |
| Eastern Cooperative Oncology Group (ECOG) performance status | 0 | 321 (62.7%) |
| 1 | 148 (28.9%) | |
| 2 | 22 (4.3%) | |
| 3 | 1 (0.2%) | |
| Missing | 20 (3.9%) | |
| Tumor stage at study entry | Locally advanced | 67 (13.1%) |
| Metastatic *** | 406 (79.3%) | |
| Lung metastases | 289 (56.4%) | |
| Bone metastases | 102 (20.0%) | |
| Other metastases | 285 (55.7%) | |
| Both | 36 (7.0%) | |
| Missing | 3 (0.6%) | |
| Prior treatments | Prior surgery Yes No |
433 (84.6%) 79 (15.4%) |
| Prior radio therapy Yes No Missing |
171 (33.4%) 314 (61.3%) 27 (5.3%) |
|
| Prior chemotherapy (N = 503) Yes No Missing |
503 (98.2%) 0 9 (1.8%) |
|
| No. of lines of prior chemotherapy; n = 503 | Median | 1.0 |
| Range (Min–Max) | 1–5 | |
| No. of lines of prior chemotherapy | 1 line | 304 (59.4%) |
| 2 lines | 139 (27.1%) | |
| ≥3 lines | 60 (11.7%) | |
| Missing | 9 (1.8%) | |
Data shown are numbers and percentages or median and range values of patients with available data. * Other histological types of sarcoma are listed in Table S1. ** Other primary sites included thoracic (lung and non-lung), head and neck, skin, perianal sites. *** Those figures include the patients with metastases (n = 406) and both locally advanced and metastatic disease (n = 36).